跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0124

Sigma-Aldrich

甲磺酸雷沙吉兰 甲磺酸酯

≥98% (HPLC)

别名:

(R)-N-2-丙炔基-1-氢化茚胺甲磺酸盐 甲磺酸酯, TVP-1012, 马来酸雷沙吉兰 甲磺酸酯

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C12H13N · CH4O3S
CAS号:
161735-79-1
分子量:
267.34
MDL號碼:
MFCD08460604
分類程式碼代碼:
12352200
PubChem物質ID:
329825174
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D +15 to +28°, c = 0.6 mg/mL in H2O

儲存條件

desiccated

顏色

white to tan

溶解度

H2O: ≥20 mg/mL

儲存溫度

2-8°C

SMILES 字串

CS(O)(=O)=O.C#CCN[C@@H]1CCc2ccccc12

InChI

1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1

InChI 密鑰

JDBJJCWRXSVHOQ-UTONKHPSSA-N

基因資訊

human ... MAOB(4129)

應用

甲磺酸雷沙吉兰可被用于MAO B型介导的细胞信号转导研究。
甲磺酸雷沙吉兰已被用于：
  • 通过细胞凋亡调节因子Bax/Bcl-2的调节来检测其对视网膜色素变性（RP）的神经保护作用
  • 在1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）诱导的小鼠模型中用作单胺氧化酶-B抑制剂
  • 作为一种抗帕金森病药物，用于测试其对6-羟基多巴胺损伤的斑马鱼幼体运动迟缓和运动障碍样行为的拯救功能

生化／生理作用

甲磺酸雷沙吉兰是单胺氧化酶的一种不可逆抑制剂，其对B型MAO的选择性比A型高十四倍。它具有抗凋亡和神经保护活性，并已被用于治疗帕金森病。
甲磺酸雷沙吉兰是帕金森病早期的一种有效治疗选择。它可改善左旋多巴治疗患者的运动波动，并对此类患者可能是一种有用辅助手段。它具有神经保护作用并可增加多巴胺能神经元的存活。

特點和優勢

该化合物是《受体分类及信号转导》手册上多巴胺和去甲肾上腺素代谢 和 组胺合成和代谢页面上的推荐化合物。想要浏览手册的其他页面， 请单击此处。

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
126M4704V
013M4727V
091M4727V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Rita L Vaz et al.
Pharmacology, biochemistry, and behavior, 189, 172828-172828 (2019-12-01)
Parkinson's disease (PD) is known as a movement disorder due to characteristic motor features. Existing therapies for PD are only symptomatic, and their efficacy decreases as disease progresses. Zebrafish, a vertebrate in which parkinsonism has been modelled, offers unique features
Dhaval R Kalaria et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 204-212 (2018-02-27)
Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist)
J M Rabey et al.
Clinical neuropharmacology, 23(6), 324-330 (2001-09-29)
Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability
J P Finberg et al.
Neuroreport, 9(4), 703-707 (1998-04-29)
Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also
O Rascol et al.
Lancet (London, England), 365(9463), 947-954 (2005-03-16)
Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and
查看所有相关文献

商品

Histamine Synthesis and Metabolism

Our company offers many products related to histamine synthesis and metabolism for your research needs.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门